Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

1. [European journal of nuclear medicine and molecular imaging · 2025
   Trial
2. Whole-body MRI Versus [ 18 F]FDG PET/CT in Diagnosing and Monitoring Plasmacytomas : A Comparative Study.Clinical nuclear medicine · 2025
   Article
3. Laser isotope separation ofScientific reports · 2023
   Article
4. Extended X-ray absorption fine structure spectroscopy measurements andiScience · 2022
   Article
5. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules (Basel, Switzerland) · 2021
   Review
6. The realities of radium.Nature chemistry · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as